P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e0036307
10.1097/01.hs9.0000970352.00363.07